Biochemical Non-Invasive Prediction of Hepatic Fibrosis in Patients with Chronic Hepatitis C Genotype 4

Amr Amin*, Mohammed Mukhtar†, Essam NoorEldin‡, Fahd Gethami, Fayeza Hafez, Sameer Fatani, Neda Bogari, Abdullatif Babakr, Soud Khogeer, Ahmed Fawzy*

*Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, KSA  
†Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt  
‡King Faisal Hospitals, Shesha, Makkah, KSA  
§Medical Genetics Department, Faculty of Medicine, Umm Al-Qura University, Makkah, KSA  
**Division of Human Genetics and Genome Research, Department of Molecular Genetics and Enzymology, National Research Centre, 33Bohouth St. Dokki, Giza, Egypt

ABSTRACT

Objectives: Hepatic fibrosis detection is considered as a major independent predictor of treatment response in patients with chronic hepatitis C. Liver biopsy, represents the "gold standard" for evaluating liver fibrosis, however this method has prone sampling errors and completions. Currently used noninvasive predictors of fibrosis are considered less accurate than liver biopsy. We are aiming to reduce the use of the liver biopsy and instead evaluate the performance value of serum hyaluronic acid (HA), Collagen type IV (Coll-IV), and AST to platelet ratio index (APRI) as non-invasive diagnostic and stratification markers for hepatic fibrosis. Design and methods: 104 Saudi patients with chronic hepatitis C genotype 4 were recruited for this study. Liver histopathological staging (F) was determined and serum hyaluronic acid and Collagen-IV were measured using ELISA techniques where, APRI was calculated. Results: Both Collagen-IV and APRI significantly distinguished fibrotic patients from non-fibrotic group. The HA, APRI, and Coll-IV results discriminate early F0/F1 from F2/F3 (p<0.001). A combination of direct and indirect tests (Coll-IV and APRI) improved the performance with sensitivity and specificity. Conclusions: The combination of APRI and Collagen-IV has a high diagnostic value in predicting moderate and severe fibrotic stages and could be clinically used as a diagnostic test especially for those HCV patients who could not be submitted for liver biopsy.

1. Introduction

Hepatitis C is a global socio-medical health problem. Hepatitis C virus genotype 4 (HCV-4) is the most prevalent genotype in Saudi Arabia. Despite the reported declines in HCV prevalence, the disease continues to represent a major public health problem in the country with a significant morbidity and mortality as well as a great burden on the country’s healthcare system. Chronic infection with HCV induces the progression of liver fibrosis. HCV infection of the human liver myo-fibroblast triggers extracellular matrix overproduction, thereby contributing to the development of HCV-related liver fibrosis which implies possible progression to cirrhosis. HCV genotypes may be correlated with severity of liver disease. The genotypes of HCV are unequally distributed throughout the world where, Types 1 and 3 are most common in Europe and the United States, while, Genotype 4 is common in the Middle East, Egypt, and central Africa. Genotyping in HCV patients is important for designing the therapeutic strategies where patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult population to treat.

Fibrosis and cirrhosis are different degrees of loss of structure and function of the liver. Currently, the only effective treatment for cirrhosis is liver transplantation, while early diagnosis and treatment of fibrosis is possible and will improve survival and reduce the need for liver transplantation. Fibrosis stage is one of the factors that affect the decision to treat HCV-patients soon or
delay the treatment. The reference standard for diagnosing the extent of fibrosis in chronic liver disease is the invasive liver biopsy (LB), which provides useful information on numerous processes such as inflammation, necrosis or steatosis, but may be accompanied by potential serious complications that have led to the development of noninvasive methods to replace LB. In addition, other disadvantages of liver biopsy are reported including that it does not efficiently reflect the fibrotic changes occurring in the entire liver due to the sample size. Biopsies from different areas have shown different stages of fibrosis causing the disagreements between pathologists as well as the increased cost of treatment and prolonged hospitalization.

Nowadays, non-invasive liver tests including serum tests and imaging (Fibro-scan) are alternatives to biopsy in Europe and other areas of the world. Both have demonstrated a reasonable ability to identify significant fibrosis and replaced the histological procedure in clinical practice in the staging of fibrosis in patients with hepatitis C. Since the typical mechanism underlying the development of hepatic fibrosis is an imbalance between the deposition and removal of extracellular matrix, direct markers evaluate the turnover or metabolism of the extracellular matrix in the peripheral blood and hence, the assessment involves dynamic processes such as fibrogenesis or fibrolysis rather than existent fibrosis. Different direct markers are used where liver fibrosis prediction including cytokines and several glycoproteins such as hyaluronic acid produced by hepatic stellate cells and the collagen family, as its production is induced by fibrosis, where they use the employment of a single or combined routine hematological or biochemical tests that reflect alteration of hepatic function. The most frequently included indirect markers are platelets count, the ratio of aspartate to alanine transaminases (AST/ALT ratio), and the ratio index of AST to platelets (APRI). Until now, the accuracy of these indirect markers is controversial. Moreover, a major limitation of all these non-invasive liver tests is the absence of uniformly established and validated cut-offs for fibrosis stages. Various direct and indirect tests have been combined in patented commercial algorithms that improve the diagnostic accuracy of tests. Establishing accurate staging of liver disease is very important for enabling both therapeutic decisions and prognostic evaluations. The determination of the non-invasive markers accuracy in staging of liver fibrosis is important, especially in the regions where different HCV genotypes - that associated with more severity of liver disease - are common rather than those widespread in Europe. The rate of adoption of different direct and indirect non-invasive biomarkers in prediction of liver fibrosis differs from country to country, but remains limited. As liver fibrosis differs in the distribution within the liver and in the fibrogenic process itself, therefore, each non invasive biomarker or panel is in need to be evaluated across a variety of clinical cohorts in addition to genotyping identification. We are aiming in this study to assess the efficiency and the performance of a panel of non-invasive markers (including two direct markers -Collagen-IV and Hyaluronic acid- and one indirect marker, APRI) to predict fibrosis stage in our patients with chronic HCV-4.

2. Patients & Methods

2.1 Patients Selection: This study was conducted in accordance with the declaration of Helsinki. The ethical committee and institutional review board (IRB) of the faculty of Medicine, Umm Al-Qura University, Saudi Arabia, approved the protocol including both well-constructed questionnaire and an informed consent that obtained from individual patients. Out of 202 patients with chronic hepatitis liver disease who attended the outpatient clinic of King Faisal Hospital, in Makkah, Saudi Arabia during 2012 to 2014 (with indicated liver biopsy), a total of 167 positive HCV-RNA-patients were enrolled in this study. The diagnosis of chronic liver disease (CLD) was done on the basis of clinical picture, ultra-sonography findings, liver function profile, and endoscopy. Liver fibrosis staging indicated for these patients were carried out through histopathological examination of liver biopsy, classified using METAVIR classification. Detailed clinical history and clinical examinations were undertaken. All 167 patients were checked for HCV-genotype using nested PCR/RFLP technique. One hundred four patients (104) were genotyped as genotype-4 (66 men and 38 women, aged 32 – 68 years). In addition; fifty healthy control-volunteers were recruited with no significant history of liver disease, negative for HCV-Ab/HBsAg/HBcIgG, and with normal liver enzymes at the time of collection. The fibrosis staging used in the analysis of the study was classified according to METAVIR scoring system into fibrosis score (F) that defined (table 1).

Table1: Hepatocyte fibrosis stages classification system

<table>
<thead>
<tr>
<th>Fibrosis score (F)</th>
<th>Stage description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F0</td>
<td>No significant fibrosis</td>
</tr>
<tr>
<td>F1</td>
<td>portal fibrosis without septa</td>
</tr>
<tr>
<td>F2</td>
<td>portal fibrosis with rare septa</td>
</tr>
<tr>
<td>F3</td>
<td>Abundant bridging fibrosis</td>
</tr>
<tr>
<td>F4</td>
<td>cirrhosis or advanced scarring of the liver</td>
</tr>
</tbody>
</table>

3. METHODOLOGY:

3.1 Biochemical and Immunological Quantitative Analysis

All groups underwent serological assessment of liver enzymes [Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)], complete blood picture (CBC), and quantitative measurements of hyaluronic acid (HA), Collagen IV in addition to Aspartate-Platelet Ratio Index (APRI) score-calculation. Collagen IV (Coll-IV) was measured using the ELISA Kit for Collagen Type-IV (SEA180Hu, Cloud-Clone Corporation, USA) using pre-coated micro-titer plate coated with an antibody specific to Coll-IV. The concentration of Coll-IV in the samples is determined by comparing the absorbance of the samples to the standard curve.
Hyaluronic acid (HA) was measured using the TECO® ELISA assay kit (TE1017-2, TECO medical Group, Switzerland) using a micro-titer pre-coated plate with HA binding protein (HABP) and HRP conjugated HABP for detection. The concentration of HA in the samples is determined by comparing the absorbance of the samples to the standard curve. APRI is a simple and inexpensive calculation method based on the platelet count and AST value to check for liver fibrosis. The score is calculated according to the following the formula:

\[
\text{APRI} = \frac{\text{AST (IU/L)}}{\text{Platelet count (109/L)}} \times 100
\]

Note: 40 IU/L is the upper limit for AST

3.2 Molecular Analysis

HCV RNA was extracted from fifty μl of serum using high pure viral RNA extraction kit according to the manufacturer's instructions (ROCHE Diagnostic GmbH, Mannheim, Germany). cDNA was synthesized from 7 μl of RNA with 200 U of AMV reverse transcriptase (Promega, USA) using a BIORAD UV-transilluminator for identifying desired 234bp fragment using molecular weight marker.

 Nested PCR : cDNA was transcribed using specific outer antisense primer from 5’ noncoding region (NCR)-core region. Direct PCR was performed with the cDNA in the reaction mixture of a total reaction volume of 25 μl containing 250 μmol/μl dNTPs, 0.75 U Taq DNA polymerase, PCR buffer (10 X), 2.5 mmol/μl MgCl2, (MBI Fermentas, Lithuania), and 20 pmol primers, P1 and P2 for 5’-NCR–core region (table 2). Nested PCR was performed in the reaction mixture containing PCR buffer (10X), 2.5 mmol/μl MgCl2, 250 μmol/μl dNTPs, 0.75 U Taq DNA polymerase, 20 pmol primers F3 and P4 for 5’-NCR–core region (table 2). Both the 1stand 2nd rounds of nested-PCR were composed of thirty five cycles programmed as the following conditions: denaturation at 94°C for 3 min, followed by 35 cycles of amplification for 45 sec each at 94°C, 55°C, and 72°C and finally 5 min at 72°C for final extension. The 2ndamplified product was then electrophoresed with ethidium bromide in a 2 % agarose gel (Sigma-Aldrich, USA) and visualized using a BIORAD UV-transilluminator for identifying desired 234bp fragment using molecular weight marker.

 RFLP genotyping: Following Constantine et al protocol, HCV genotype identification was carried out using restriction fragment length polymorphism (RFLP). Ten μl from the nested PCR products of from the 5’ noncoding region 234bp, were digested by restriction endonucleases, Rsal, HaeIII in buffer L (Boehringer Manheim, Germany). Bands corresponding to specific 5’ NCR sequences were revealed in case of combination of the three markers as a panel, with sensitivities of (86.5% and 86.6% respectively). Highest sensitivity (92%) was revealed in case of combination of the three markers as a panel, with specific 5’ NCR sequences were visualized under UV transilluminator and identified according to specific recognition sequence.

### Table 2: primers sequence used for the nested PCR

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outer P1</td>
<td>030-054</td>
<td>5’GTG AGG AAC TAC TGT CTT CAC GCAAG3’</td>
</tr>
<tr>
<td>Outer P2</td>
<td>307-331</td>
<td>5’TGC TCA TGG TGC AGC GTG TAC GAGA3’</td>
</tr>
<tr>
<td>Inner P1</td>
<td>046-065</td>
<td>5’TTC ACG CAG AAA GCG TCT AG5’</td>
</tr>
<tr>
<td>Inner P4</td>
<td>262-282</td>
<td>5’CTA TGC GGC AGT ACC ACA AGG3’</td>
</tr>
</tbody>
</table>
a specificity, positive predictive value and accuracy of (81.2%, 88.4%, and 87.8%, respectively). Using Pearson's correlation that revealed highly significant positive correlation between each two markers of the study, especially between APRI and Coll-IV, r = 0.72, p<0.01 (table 5).

**Table (3):** Mean levels of non-invasive diagnostics in Fibrotic HCV-4 patients with different METAVIR stages and controls.

<table>
<thead>
<tr>
<th>Control</th>
<th>Fibrotic HCV-4</th>
<th>F0</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F-test</th>
<th>F value</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRI</td>
<td>2.65</td>
<td>1.861</td>
<td>0.011</td>
<td>0.511</td>
<td>0.711</td>
<td>0.711</td>
<td>1.544</td>
</tr>
<tr>
<td>Coll-IV</td>
<td>0.05</td>
<td>0.011</td>
<td>0.511</td>
<td>0.711</td>
<td>0.711</td>
<td>0.711</td>
<td>1.544</td>
</tr>
<tr>
<td>HA</td>
<td>0.78</td>
<td>0.011</td>
<td>0.511</td>
<td>0.711</td>
<td>0.711</td>
<td>0.711</td>
<td>1.544</td>
</tr>
<tr>
<td>Coll-IV</td>
<td>0.87</td>
<td>0.011</td>
<td>0.511</td>
<td>0.711</td>
<td>0.711</td>
<td>0.711</td>
<td>1.544</td>
</tr>
<tr>
<td>APRI</td>
<td>0.87</td>
<td>0.011</td>
<td>0.511</td>
<td>0.711</td>
<td>0.711</td>
<td>0.711</td>
<td>1.544</td>
</tr>
</tbody>
</table>

Table (4): Diagnostic accuracy of different studied markers for fibrosis prediction using optimal ROC curves.

<table>
<thead>
<tr>
<th>Fibrosis stage</th>
<th>Cut off</th>
<th>SD</th>
<th>Sp</th>
<th>NPV</th>
<th>PPV</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA ng/ml</td>
<td>F0,1,2,3</td>
<td>93.9</td>
<td>53.8</td>
<td>60.0</td>
<td>38.4</td>
<td>73.0</td>
</tr>
<tr>
<td>Coll-IV ng/ml</td>
<td>F0,1,2,3</td>
<td>97.0</td>
<td>73.0</td>
<td>75.0</td>
<td>58.0</td>
<td>85.0</td>
</tr>
<tr>
<td>APRI</td>
<td>F0,1,2,3</td>
<td>80.4</td>
<td>60.0</td>
<td>76.6</td>
<td>87.7</td>
<td>65.2</td>
</tr>
</tbody>
</table>

Vs: versus; Cont.: control; Se: sensitivity; Sp: specificity; a: true positives/true positives + false negatives; b: true negatives/false negatives + false positives; d: true negatives/true negatives + false negatives. HA: hyaluronic acid; NPV: negative predictive value; Coll-IV: Collagen IV; APRI: Aspartate/Platelet count Ratio Index; PPV: positive predictive value. AUC: The area under the curve representing the accuracy of the test (The higher value near to 1.0 is the more discrimination ability of the test).

Table (5): Correlation between APRI, HA, and Collagen IV biomarkers

<table>
<thead>
<tr>
<th></th>
<th>Pearson Correlation</th>
<th>Sig. (2-tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA</td>
<td>0.55</td>
<td>0.001</td>
</tr>
<tr>
<td>Coll-IV</td>
<td>0.72</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Discussion:

In the present study, we were found a panel of direct non-invasive serum markers of extra-cellular matrix (ECM), Hyaluronic acid (HA), Collagen IV (Coll-IV), and indirect marker (Aspartate/Platelet count Ratio Index, APRI) individually and in combine to be a significant predictors of liver fibrosis in HCV-4 infected patients in comparison to liver biopsy results.

Worldwide, thirty millions out of 150 millions chronic hepatitis C patients are exposed to health deterioration due to cirrhosis progression. Chronic infection with HCV triggers extracellular matrix over-production induces the progression of liver fibrosis, thereby, contributing to the development of HCV-related liver fibrosis. An association is reported between different HCV genotypes and severity, aggressiveness, and histological pattern of liver fibrosis. Hepatitis C virus genotype 4 (HCV-4) is the most prevalent genotype in Saudi Arabia with a significant morbidity and
mortality as well as a great burden on the country’s healthcare system. Liver fibrosis stratification is an essential factor that should be considered in the management of patients with HCV. Despite genotype identification and fibrosis stratification in HCV patients is important for designing the therapeutic strategies, a great debate is still current about the best simple efficient method used for liver fibrosis assessment that could help hepatologists in the decision of management which could reduce 30% of the HCV related-deaths by 2030.

While liver biopsy is still used in the USA for liver fibrosis assessment, it has been largely replaced in Europe and other areas of the world by blood markers and/or fibro-scan. A growing medical attention is performed to select non-invasive bio markers that can accurately predict the fibrosis progression. Although, fibrosis diagnosis of F0-F2 is considered a factor in decision of speed up treatment of HCV-infected patients, the results of fibrosis prediction tools to discriminate the stages of fibrosis between F1 and F3 are not completely validated. Combinations of simple laboratory tests that reflect the underlying pathophysiology of liver fibrosis increase possibility to exclude severe fibrosis.

Among 167 positive HCV-RNA infected-patients subjected for genotyping in this study, only 104 patients (62%) were HCV-4 using nested PCR/RFLP analysis. Liver biopsy was indicated and performed for all patients. Fibrosis was staged on a scale of 0 to 3: F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = portal fibrosis and few septa, F3 = numerous septa without cirrhosis according to the METAVIR score system. None of the patients staged as F4 could be collected from histopathology and hence, not involved in the study. All 104 positive HCV-RNA genotype 4 patients were recruited and compared to 50 healthy-control group. In the present study, we evaluated the accuracy of a panel of direct non-invasive serum markers of extra-cellular matrix (ECM), Hyaluronic acid (HA), Collagen IV (Coll-IV), and indirect marker (Aspartate/Platelet count Ratio Index, APRI) individually and in combine to predict liver fibrosis in HCV-4 infected patients in comparison to liver biopsy results. While Figure 1 showed increase in the mean levels for the three examined markers with different liver fibrosis stages (F0,1,2,3), Table (3) revealed that only two of them, Coll-IV and APRI markers showed significant increase in levelin the fibrotic HCV-4 patients (Mean ± SEM 1.3 ± 0.05ng/ml and 1.06 ± 0.06 ng/ml versus healthy group mean levels of 0.87 ± 0.05ng/ml and 0.45 ± 0.02 ng/ml for Coll-IV and APRI, respectively). A significant correlation between Coll-IV serum concentration and progression.

The ROC curves showed that the optimal cutoff value that maximizes the sum of both sensitivity and specificity of Coll-IV to screen HCV-4 patients for fibrosis was >0.97 ng/ml with a moderate sensitivity, specificity, NPV and PPV of75%, 73%, 58%, and 85%, respectively. The diagnostic efficacy was shown with Coll-IV cut-off value of 1.3 ng/ml to distinguish both moderate and severe stage F≥2 of fibrosis with sensitivities 65%, and specificity of86.7%. These findings are close to those reported by many researchers elsewhere (with different cut-off values) who studied the coll-4 but in different liver pathogenic disease-induced fibrosis including NAFLD and HCV-patients. Aida et al. reported lower cut off value 0.7 with an estimated sensitivity of 77% and specificity of 72% for detection of liver fibrosis associated with hepatitis and cut off value of 1.0 for fibrosis F≥2 using METAVIR classification with sensitivity and specificity of 61% and 64%, respectively). Liu et al. reported lower APRI cut off values, 0.11 and 0.18 for different ages of patients to identify CHB patients with insignificant fibrosis, where, Yilmaz et al. chose an optimal cut off value >0.44 for CHC patients with sensitivity 72.7% and a specificity of 62.4% for diagnosis of fibrosis (1-4). Kruger et al. calculated an optimal cut-off of 0.98 (AUC 0.85), resulting a sensitivity of 75% and specificity of 86% for prediction of advanced fibrosis stages in NAFLD patients. These results of APRI support our suggestion that these variations in APRI cut off values may be related to many factors including differences in sample size, different etiology of liver fibrosis (NAFLD, CHB, Co-infection with HIV, CHC with genotype variations), with the influence on the mechanism of fibrosis progression.

In our study, using area under the ROC curve, APRI provided the best accurate results of discrimination ability to exclude patients without fibrosis from those HCV-4 with early fibrosis changes parallel to METAVIR score of at least F0/F1(AUC, 0.931) in comparison to the other two non-invasive liver fibrosis tests, Coll-IV and HA AUC 0.819 and 0.563, respectively, the APRI cut-off point being >0.6 for HCV-4 patients showed higher sensitivity (80.4%) with moderate specificity (76.6%) and with predictive values;87.7% PPV and 65.2% NPV in HCV-4 indicating moderate ability to predict fibrotic changes. However, using of cut off value 0.91 increased the specificity to 93.7 with sensitivity 81.1% and PPV of 96.9% in discrimination of moderate and severe fibrosis stages (F≥2) compared to early stages F0 and F1 (AUC 0.917). Aida et al. set almost the same cut off value 0.9 for severe fibrosis prediction in HCV-infected patients with 78% sensitivity and 68.6% specificity. Close cutoff values to that results in our study were reported by Lin et al., who performed a large meta-analysis included more than 8,700 patients on hepatitis C virus (HCV) mono-infected and HCV/human immunodeficiency virus (HIV) co-infected individuals reporting APRI cut off value 0.7 with an estimated sensitivity of 77% and specificity of 72% for detection of liver fibrosis associated with hepatitis and cut-off value of 1.0 for fibrosis F≥2 using METAVIR classification with sensitivity and specificity of 61% and 64%, respectively). Liu et al. reported lower APRI cut off values, 0.11 and 0.18 for different ages of patients to identify CHB patients with insignificant fibrosis, where, Yilmaz et al. chose an optimal cut off value >0.44 for CHC patients with sensitivity 72.7% and a specificity of 62.4% for diagnosis of fibrosis (1-4). Kruger et al. calculated an optimal cut-off of 0.98 (AUC 0.85), resulting a sensitivity of 75% and specificity of 86% for prediction of advanced fibrosis stages in NAFLD patients. These results of APRI support our suggestion that these variations in APRI cut off values may be related to many factors including differences in sample size, different etiology of liver fibrosis (NAFLD, CHB, Co-infection with HIV, CHC with genotype variations), with the influence on the mechanism of fibrosis progression.
stages 0–2, 149.4 ± 15.9 ng/mL for stages 3–4, and 284.5 ± 14.5 ng/mL for stages 5–6. We selected the cut-off value 93.9 ng/mL as the upper limit of normal HA with achieving best sensitivity and specificity (53.8% and 60%, respectively) and predictive values of 57.6% and 60% for both PPV and NPV, respectively. Where, increasing the HA cut off value to 110 ng/mL revealed a significant difference to discriminate severe fibrosis stage (F2) compared to early stages (F0–1) with 64.9% sensitivity and a specificity of 100% with high PPV 100% and NPV of 53.6% and AUC of 0.944 indicating good diagnostic ability to predict both moderate and severe fibrosis (F2–3). We compared our results to those reported for HA to diagnose or stratify fibrosis, Stibbe et al. reported HA cut off value 0.86 ng/mL distinguishing F0123 from F4 (p<0.001) in 89 patients of chronic viral hepatitis B and C with a corresponding AUC (95% CI) which was in concordance with cut off value 0.799 ng/mL selected by Aida et al. to discriminate severe fibrosis, stage 3/4 in 187 chronic hepatitis C. Resino et al. studied 2011HV/Hepatitis C co-infected patients for fibrosis prediction using noninvasive HA measurement, reporting HA cut-off 1182 ng/mL to exclude cirrhosis (F4) with a NPV of 99% and cut-off value 2400 ng/mL to confirm cirrhosis (F4). Geramizadeh et al., reported HA cut-off value <113 ng/mL for fibrosis detection in 93 HBV infected-patients with sensitivity 92%, specificity 95%, PPV 89%, and PPV 94%, the cut off raised to >181 ng/mL for severe fibrosis detection, achieving 100% sensitivity, 95% specificity, 100% NPV, and 78% PPV. Halon et al. reported HA cut off values to predict significant fibrosis, severe fibrosis, and cirrhosis of 121, 160, and 237 ng/mL, respectively with PPV of 94%, 100%, and 57%, respectively. Several studies have been performed with HA using other ranges of cut-off values (16 – 160 ng/mL) to exclude cirrhosis with variable PPV indicating HA as a biomarker for high score fibrosis and cirrhosis. However, setting of these previously described cut-offs reduces our data sensitivity in excluding severe fibrosis. These above values variations (from 0.799ng/mL to 2400 ng/mL) may be related to the difference in manufacturing kits.

Significant correlations using Pearson correlation (2-tailed) between the three parameters was shown, (p>0.001), table (5). Testing the pattern of stages results using Scheffe method (Post Hoc analysis), significant correlation between both early stages, F0 and F1, moderate, and severe stages (F2 and F3) was recorded. Enhancement of diagnostic performance for the detection of different liver fibrosis stages was achieved using combination of the three studied tests. Improvement in the sensitivity, specificity, and accuracy was observed for each biomarker when combined with each other. Increased sensitivity 91.8% was shown in case of both APRI and Coll-IV combination with specificity, NPV, and PPV 78.7%, 86.6%, and 86.5%, respectively. Higher sensitivity (92%) was achieved in case of the three markers combined panel, with specificity, PPV, NPV and accuracy (81.2%, 88.4%, 86.6%, and 87.8%, respectively).

Conclusion:
Among non-invasive liver fibrosis biomarkers, APRI has the highest diagnostic value in discriminating liver fibrosis stages (F2–3) for patients with HCV genotype 4. Clinically, combination of direct and indirect non-invasive serum biomarkers, Collagen IV and APRI is suggested to screen HCV-4 patients for moderate and severe fibrosis. This allows physicians to define severe fibrotic patients, especially for those patients who couldn’t be submitted for liver biopsy.

Abbreviations
RFLP: Restriction Fragment length polymorphism; PCR: Polymerase chain reaction; CHC: Chronic hepatitis C; ROC: Receiver operating characteristics; AUC: Area under the curve; HCV-4: HCV genotype 4; HBsAg: Hepatitis B surface antigen; NAFLD: Non-alcoholic fatty liver disease

Authors’ contribution
AA and AF have made substantial contributions to acquisition of data and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; 3) have given final approval of the version to be published; and 4) agree to be accountable for all aspects of the work in ensuring that questions. HB and SK carried out the biochemical assays. MM, EN and FG participated in the design of the study and performed the statistical analysis with some laboratory work. FH, NB and MN have made substantial contributions to conception and design of the study, and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgment:
We thank all the participants in the study for their enthusiastic collaboration, in particular the personnel of the governmental clinics in Makkah. We acknowledge the Institute of Scientific Research and Revival of Islamic Heritage at Umm Al-Qura University for his financial support for this study.

Conflict of interest
We declare no conflict of interest. No, there are any competing financial interests in relation to the work described.

References:


